VALUE OF SERUM ALPHA L FUCOSIDASE LEVEL AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA BEFORE AND AFTER CHEMO-EMBOLIZATION AND RADIO-FREQUENCY, A PROSPECTIVE STUDY
Because hepatocellular carcinoma (HCC) is a complex disease with multiple risk pathogenic mechanisms due to misdiagnosis with a single biomarker. A combination of biomarkers may be more valuable for the diagnosis, staging and prognosis of HCC. In the near future, identifying non-invasive and cost-effective biomarkers for early diagnosis and personalized treatment of HCC will be one of the most promising fields of biomarker research. This study assessed the alpha L fucosidase (AFU) value as a prognostic biomarker in patients with HCC before and after chemo-embolization and radio-frequency. A total of 60 subjects were subdivided into 3 groups: GI: 30 HCC patients underwent interventional management (chemo-embolization or radiofrequency), GII: 20 liver cirrhosis (LC) patients and GIII: 10 cross-matched individuals as control The results showed that plasma AFU had significantly higher diagnostic performance in HCC diagnosis than alpha fetoprotein (AFP) at a cut off value of > 2.5u/l, with sensitivity 100%, specificity 95%, positive predictive value (PPV) 96.8%, negative predictive value (NPV) 100% and diagnostic accuracy 98%. Basal pre-intervention AFU) had significantly high diagnostic performance to predict HCC recurrence after intervention at a cut off value of > 12.5u/l with sensitivity 100%, specificity 92%, PPV, 71.4%, NPV 100% and diagnostic accuracy 93.3%. Postintervention AFU had significant moderate diagnostic performance in predicting recurrence of HCC at cut off value of > 7.5u/l with sensitivity 80%, specificity 92%, positive predictive value (PPV) 66.7%, negative predictive value (NPV) 95.8% & diagnostic accuracy 90%.
ABO HALIMA, A., KEDDEAS, M. W., & KAISAR, H. H. (2021). VALUE OF SERUM ALPHA L FUCOSIDASE LEVEL AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA BEFORE AND AFTER CHEMO-EMBOLIZATION AND RADIO-FREQUENCY, A PROSPECTIVE STUDY. Journal of the Egyptian Society of Parasitology, 51(2), 377-384. doi: 10.21608/jesp.2021.193321
MLA
AHMED SAMIR ABO HALIMA; MARCEL WILLIAM KEDDEAS; HANY HAROUN KAISAR. "VALUE OF SERUM ALPHA L FUCOSIDASE LEVEL AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA BEFORE AND AFTER CHEMO-EMBOLIZATION AND RADIO-FREQUENCY, A PROSPECTIVE STUDY". Journal of the Egyptian Society of Parasitology, 51, 2, 2021, 377-384. doi: 10.21608/jesp.2021.193321
HARVARD
ABO HALIMA, A., KEDDEAS, M. W., KAISAR, H. H. (2021). 'VALUE OF SERUM ALPHA L FUCOSIDASE LEVEL AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA BEFORE AND AFTER CHEMO-EMBOLIZATION AND RADIO-FREQUENCY, A PROSPECTIVE STUDY', Journal of the Egyptian Society of Parasitology, 51(2), pp. 377-384. doi: 10.21608/jesp.2021.193321
VANCOUVER
ABO HALIMA, A., KEDDEAS, M. W., KAISAR, H. H. VALUE OF SERUM ALPHA L FUCOSIDASE LEVEL AS A PROGNOSTIC BIOMARKER FOR HEPATOCELLULAR CARCINOMA BEFORE AND AFTER CHEMO-EMBOLIZATION AND RADIO-FREQUENCY, A PROSPECTIVE STUDY. Journal of the Egyptian Society of Parasitology, 2021; 51(2): 377-384. doi: 10.21608/jesp.2021.193321
)
View on SCiNiTO